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Abstract
Background: Expression of the growth factor osteoactivin (OA) increases during tissue degeneration and
regeneration, fracture repair and after denervation-induced disuse atrophy, concomitant with increased matrix
metalloproteinases (MMPs). However, OA’s expression with repetitive overuse injuries is unknown. The aim of this
study was to evaluate: 1) OA expression in an operant rat model of repetitive overuse; 2) expression of MMPs; 3)
inflammatory cytokines indicative of injury or inflammation; and 4) the inducible form of heat shock protein 70
(HSPA1A/HSP72) as the latter is known to increase during metabolic stress and to be involved in cellular repair.
Young adult female rats performed a high repetition negligible force (HRNF) food retrieval task for up to 6 weeks
and were compared to control rats.
Methods: Flexor digitorum muscles and tendons were collected from 22 young adult female rats performing a
HRNF reaching task for 3 to 6 weeks, and 12 food restricted control (FRC) rats. OA mRNA levels were assessed by
quantitative polymerase chain reaction (qPCR). OA, MMP-1, -2, -3, and -13 and HSP72 protein expression was
assayed using Western blotting. Immunohistochemistry and image analysis was used to evaluate OA and HSP72
expression. ELISA was performed for HSP72 and inflammatory cytokines.
Results: Flexor digitorum muscles and tendons from 6-week HRNF rats showed increased OA mRNA and protein
expression compared to FRC rats. MMP-1, -2 and -3 progressively increased in muscles whereas MMP-1 and -3 increased
in tendons with HRNF task performance. HSP72 increased in 6-week HRNF muscles and tendons, compared to controls,
and co-localized with OA in the myofiber sarcolemma. IL-1alpha and beta increased transiently in tendons or muscles in
HRNF week 3 before resolving in week 6.
Conclusion: The simultaneous increases of OA with factors involved in tissue repair (MMPs and HSP72) supports a role
of OA in tissue regeneration after repetitive overuse.
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Background
Overuse injuries are now considered a leading cause of
long-term pain and physical disability world-wide [1], with
diagnoses including tendinopathies and muscle disorders
[2, 3]. Studies have identified repetition and duration as
two of the key risk factors for upper extremity overuse in-
juries [4]. Moreover, overuse injuries commonly occur as
a result of prolonged repetitive loading of the muscle-
tendon unit, even at low force levels [5, 6].
Several studies have shown that repetitive movements
lead to tissue injury ([7] and as reviewed in [8]). Barbe
and Barr have developed an operant rat model of upper
extremity overuse in which rats learn to perform repeti-
tive tasks, such as a high repetition negligible force
(HRNF) food retrieval task. In this particular task, rats
reach at a rate of 4 reaches/min into a portal to retrieve
a 45-mg pellet of food for 2 h/day (in four 30 min ses-
sions/day) for 3 days/week. Performance of this HRNF
task leads to modest signs of myositis and tendinitis in
forearm muscles and tendons and increased focal sites
of myotendon fray and fibroblast proliferation [9, 10].
After such tissue damage, it is known that inflamma-
tory cells infiltrate tissues, which, along with injured
cells, produce inflammatory cytokines and other me-
diators that either exacerbate damage or assist in tis-
sue repair [11, 12].
Osteoactivin (OA) is a type I transmembrane protein
that is also known as glycoprotein nonmelanoma protein
B (GPNMB). OA is a growth factor involved in tissue
turnover during regeneration [13–15] and is known to
up-regulate the expression of matrix metalloproteinases
(MMPs) in fibroblasts infiltrating denervated muscle,
leading to increased extracellular matrix (ECM) turnover
[16]. OA increases in tissue matrices during fracture re-
pair [13] and influences adhesion and migration of select
cell types (including fibroblasts) that are involved in tis-
sue repair [17], and regulates muscle regeneration in
desmin-deficient cardiomyocytes [18]. In a process called
ectodomain shedding, the extracellular fragments of
OA are cleaved on the plasma membrane and re-
leased to the ECM where they act as cytokines or
growth factors [19–21] in addition to increasing MMP
production [14]. While it is clear that OA increases under
several types of repair and regeneration conditions, its ex-
pression in association with overuse injuries has yet to be
examined.
The inducible form of HSP70 (HSPA1A; commonly
known as HSP72) mediates tissue repair after injury and
protects skeletal muscle from atrophy, damage and dys-
trophy [22–26]. HSP70/72 plays a role in skeletal muscle
repair or regeneration and adaptation after high-force
eccentric exercise [27–29] and increases concomitant
with MMP-2 in skeletal muscle following high intensity
training [30], apparently acting together to promote
muscle matrix remodeling [31]. Increased expression of
HSP70 following muscle injury regulates both the early
inflammatory and regenerative phases of muscle regen-
eration [32].
Our goals here were to evaluate the temporal and
spatial expression of OA, MMPs and HSP72 in forelimb
flexor digitorum muscles and tendons in rats performing
a HRNF task for 3 to 6 weeks. Inflammatory cytokines
were also examined in order to determine if injury/in-
flammatory processes were present in the tissues at
the same time points. Although OA has yet to be
studied in a model of overuse, we hypothesized that
it would increase in the overloaded skeletal muscles
and tendons, as would other known mediators of re-
pair (MMPs and HSP70).
Methods
Animals
All experiments were approved by the Temple Univer-
sity Institutional Animal Care and Use Committee in
compliance with NIH guidelines for the humane care
and use of laboratory animals. Rats were housed indi-
vidually in the central animal facility in transparent plas-
tic cages in a 12 h light: 12 h dark cycle with free access
to water. Studies were conducted on a total of 34 young
adult (3.5 months of age at onset of experiments)
Sprague-Dawley, female rats. All rats were handled for
1 week, and then food restricted to 80–90 % of their
naïve full body weights for another week before onset of
the experiment to motivate interest in 45 mg food pel-
lets used for reward and retrieval (Banana flavored
45 mg food pellets; Bio-Serve, Flemington, NJ). All rats
were weighed once to twice per week, provided regular
rat chow daily and allowed to gain weight over the
course of the experiments since they were young adult
rats. All rats were maintained within 5–10 % of the
weights of age-matched normal control rats (used only
for weight matching purposes and therefore not in-
cluded in the study). Rats were then randomly divided
into food restricted control rats (n = 12) and high repeti-
tion negligible force (HRNF) task rats (n = 22) perform-
ing this task for 3 weeks (n = 12) and 6 weeks (n = 10).
Behavioral task paradigm
The HRNF task has been described in detail previously
[9]. Briefly, rats were trained for 5 min/day, 5 days/week
for 10–12 days to learn to retrieve a 45-mg pellet of food
from a shoulder-height portal at a reach rate of 4
reaches/min, making this a high repetition task (i.e. fas-
ter than 30 s/cycle) [33]. After this initial training period,
task rats then performed the HRNF task for 2 h/day in
four 30 min sessions/day on 3 days/week for 3 to 6 weeks
in customized operant behavioral apparati (Med Associ-
ates, St Albans, VT), described in detail previously [9].
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Retrieval of the 45 mg food pellet from the portal was
estimated as <5 % maximum pulling force, making this a
negligible force task [34]. Rats were allowed to use their
preferred reach limb to reach and retrieve the food pel-
let, hereafter referred to as the reach limb. Tissues used
in this study were from the reach limbs.
Quantitative real-time PCR (qPCR)
Twelve animals were euthanized with an overdose of
sodium pentobarbital (120 mg/kg body weight) and fore-
arm flexor muscles were collected the flexor digitorum
mass from FRC, and 3- and 6-week HRNF rats (n = 3/
group). Each muscle belly was divided into two longitu-
dinal parts; half was used for RNA extraction and half
for protein extraction. The half for RNA extraction was
put into RNAlater RNA Stabilization Reagent (QIAGEN,
Valencia, CA) for 2 h at room temperature and then
stored at -80 °C. Total RNA was isolated using TRIzol
reagent (Invitrogen, Carlsbad, CA). The concentration of
each RNA sample was determined using a spectropho-
tometer and the integrity was monitored on 1 % formal-
dehyde denatured gels. After confirming RNA integrity
on an agarose gel, cDNA was prepared from mRNA ex-
tracts from the above tissue samples (n = 3/group) using
a High Capacity cDNA Reverse Transcription kit (Ap-
plied Biosystems™, Foster City, CA). PCR primer sets for
the following were used: OA (Cat# PPR45879B, SABios-
ciences, Frederick, MD) and GAPDH (Cat# PPR51520A,
SABiosciences, Frederick, MD). Quantitative real time
PCT (qPCR) was then performed in duplicate for 20 μl
reactions each containing 1 μl cDNA reaction mix,
100nM of each primer and 10 μl 2x SYBR® Green PCR
Master Mix method (Applied Biosystems™, Foster City,
CA), on an ABI 7500 Fast Real-Time PCR system (Ap-
plied Biosystems™). PCR cycles consisted of an initial
cycle of 50 °C for 2 min and the second cycle of 95 °C
for 10 min, followed by a two-step program of 95 °C for
15 s and 60 °C for 1 min for 40 cycles. Using GAPDH as
the internal control, relative gene expression among
samples was calculated by comparison of Ct (threshold
cycle) values. A dissociation curve was checked for each
qPCR run to confirm specific amplification of target
RNA. The PCR primer set (OA) used was purchased
from SABiosciences.
Protein isolation and western blotting
Animals were euthanized with an overdose of sodium
pentobarbital (120 mg/kg body weight) before muscle
and tendon collection from the flexor digitorum mass
from FRC rats (n = 8) and from rats that performed the
HRNF task for 3 weeks (n = 4) or 6 weeks (n = 6). As de-
scribed above, the muscles were divided into half longi-
tudinally. The half for protein analysis was snap frozen
and stored at -80 °C until homogenization and
preparation for protein analysis using previously de-
scribed methods [35, 36]. Total protein was determined
using BCA-200 protein assays (Bicinchoninic Acid,
Pierce, Rockford, IL). Then, 30 μg of protein sample was
mixed with 5X Laemmli sample buffer (Bio-Rad,
Hercules, CA) mixed with denaturing buffer, 25 % β-
mercaptoethanol, heated to 100 °C for 5 min, subjected
to sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE) and transferred at 100 V for 1 h at
4 °C to an nitrocellulose membrane (Bio-Rad) using
semi-dry transfer apparatus (Bio-Rad). The membranes
were blocked with 5 % non-fat milk in Tris-buffered sa-
line (TBS)-0.1 % Tween-20 (TBST) for 1 h at room
temperature and then incubated with the following pri-
mary antibodies: anti-rabbit beta Actin (1:1000; Sigma,
St Louis, MO), anti-mouse GAPDH (1:500; Santa Cruz
Biotechnology, Delaware Avenue, CA), anti-mouse
Hsp72 (1:300; Stressgen, Ann Arbor, MI), anti-rabbit
MMP-1 (1:500; Abbiotec, San Diego, CA), anti-mouse
MMP-2 (1:200; Abcam, Cambridge, MA), anti-rabbit
MMP3 (1:200; Novus Biologicals, Littleton, CO), anti-
mouse MMP-13 (1:200; Abcam), anti-rabbit OA/
GPNMB (1:500; Bioss Inc. Woburn, MA) and custom
made anti-chicken OA (1:250), which was produced as
previously described in [37], in blocking buffer (same as
above) overnight at 4 °C. The blot was then washed with
1X TBS-0.1 % Tween-20 (TBST) and incubated with the
following horseradish peroxidase-conjugated secondary
antibodies: donkey anti-chicken, anti-mouse or anti-rabbit
(1:5000; Jackson Immunoresearch, West Grove, PA), in
blocking buffer for 1 h at room temperature. The blot was
washed again with TBST, incubated with SuperSignal
West Pico Chemiluminescent Substrate (Thermo Sci-
entific, Rockford, IL) and exposed to film. Quantifica-
tion of the bands was performed using either Image J
or myImageAnalysis v2.0 software (Thermo Scientific).
ELISA
For protein analysis, tissues from above animals that had
been prepared for protein analysis were used in ELISAs
to determine HSP72 and inflammatory cytokine levels.
All muscle and tendon samples were homogenized sep-
arately with 0.5 to 1.0 ml RIPA buffer ((NaCl, KCl,
NaH2PO4, KH2PO4, and DDH2O +NaOH) plus EDTA
free complete protease inhibitor cocktail tablets (Roche
Diagnostics, GMPH, Germany) using a PowerGen 125
Homogenizer. Tissue homogenates were centrifuged at
14,000 rpm for 15 min. at 4 °C. Total protein was deter-
mined using BCA-200 protein assays (Bicinchoninic
Acid). For ELISA, tissue lysates (50 microliter aliquots)
were analyzed using a commercially available single-plex
ELISA kit for HSP72 (EKS-700, Stressgen, purchased
before its purchase by Enzo Life Sciences, Inc, Farming-
dale, NY), according to the manufacturers’ protocol.
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Tissue lysates were also analyzed for IL-1alpha, IL-1beta,
TNF-alpha and IL-10 using commercially available
ELISA kits according to manufacturer’s protocols (each
from BioSource International). Each sample was run in
duplicate. Data (ng protein of HSP72 and pg protein for
the cytokines) were normalized to μg total protein.
Immunohistochemical analyses and quantification
Animals received an overdose of sodium pentobarbital
(120 mg/kg body weight) before being perfused trans-
cardially with first sterile saline and then 4 % paraformal-
dehyde in 0.1 M phosphate buffer (pH 7.4): FRC (n = 6),
3-week HRNF (n = 6) and 6-week HRNF (n = 4). Tissues
were collected and postfixed “en bloc” by immersion over-
night. A proximal portion of the muscle mass was then re-
moved with a scalpel for cross-sectional sectioning while
the remaining flexor digitorum muscles and tendons were
separated as a flexor mass from the bones for longitudinal
sectioning, as previously depicted [38]. All tissues were
cryoprotected in 30 % sucrose in phosphate buffered sa-
line (PBS) before frozen-sectioning using a cryostat into
15 μm cross sectional or longitudinal slices. Sections were
then placed onto charged slides (Fisher, Super Frost Plus)
and allowed to dry overnight before storage at -80 °C.
Sections on slides were treated with 3 % H2O2 in
methanol to block for endogenous peroxidase for
30 min (if the tissues were to be used for HRP-DAP
visualization), washed in PBS, then permeabilized with
0.05 % pepsin in 0.01 N HCL prior to blocking with
10 % goat serum in PBS for 20 min at room
temperature. Sections on slides were then probed in
batches with the following primary antibodies: anti-
HSP72 (1:1000, C92F3A-5, Enzo Life Sciences, Inc) or
anti-osteoactivin (1:350, custom made anti-chicken OA)
produced and verified, as previously described [37]. On
the 2nd day after washing, one set of sections from all
groups that had been incubated with anti-OA antibody
was incubated with goat anti-chicken secondary IgG
antibody conjugated to HRP (Jackson Immunoresearch
Laboratories, West Grove, PA; diluted 1:100 in PBS, and
incubated 2 h at room temperature before washing in
PBS) and visualized using DAB (Fast DAB, Sigma).
These sections were counterstained lightly with eosin,
then dehydrated and coverslipped with DPX mounting
medium for bright field microscopy (for HRP-DAB). A
second set of sections was incubated with anti-HSP72
antibody and then with a donkey anti-mouse secondary
IgG antibody conjugated to Cy3 (red fluorescent tag) di-
luted as above (Jackson Immunoresearch Laboratories).
A third set of slides was incubated with both anti-OA
antibody and anti-HSP72 and then with appropriate
secondary antibodies conjugated to Cy2 (green fluorescent
tag) or Cy3 (red fluorescent tag) (Jackson Immunore-
search Laboratories). The fluorescent tag-labeled sections
were washed with PBS and coverslipped with 80 % gly-
cerol in PBS for epifluorescence microscopy.
The specificity of the OA and HSP72 antibodies are
shown in western blots that are part of this study. In
addition, negative control staining was performed by
omitting either the primary antibody or the secondary
antibody. No labeling was observed as a result of incuba-
tion of tissues with serum and then secondary antibodies
alone (data not shown). Preabsorption controls were
performed to demonstrate if the antibodies bound spe-
cifically to the antigen of interest. Specifically, specificity
of the OA and HSP72 antibodies was determined via the
use of recombinant human Osteoactivin/GPNMB/Fc
Chimera (Cat# 2550-AC, R&D Systems, Minneapolis,
MN) and recombinant human HSP70 protein (Product#
SPP-755, StressGen, Farmingdale, NY; purchased from
StressGen before its purchase by Enzo Life Sciences,
Inc.), respectively. A ten-fold excess of purified protein
was pre-incubated with the matching antibody overnight
at 4 °C, the mixture centrifuged and then the pre-
absorbed antibody supernatant was incubated with the
tissues (after pepsin and goat serum treatments) similar
to that described above before washing and incubation
with secondary antibodies. No labeling was observed in
the tissues for either pre-absorbed antibody (data not
shown), matching previously published specificity of the
custom made OA antibody in bone tissues [37].
The percent area with OA and HSP72 immunostaining
in muscles and tendons was quantified from HRP-DAB
stained and fluorescent stained slides, respectively. This
quantification was performed using an image analysis
program (Bioquant Osteo II, Nashville, TN) and previ-
ously described thresholded pixel count methods [39].
The person performing the quantification was blinded to
group assignment.
Statistical analysis
Statistical analyses were performed using Prism 4 and 5
(GraphPad Software, La Jolla, CA). Univariate ANOVAs
were used to analyze quantitative PCR, Western blot
densitometry and ELISA results for differences in ana-
lytes between groups. Then, post hoc analyses were
carried out using the Bonferroni test for multiple com-
parisons with FRC used as the control group and
adjusted p values are reported. An adjusted p value
of < 0.05 was considered significant for all analyses.
Data are presented as the mean ± standard error of
the mean (SEM).
Results
Increased osteoactivin in flexor digitorum muscles with
HRNF task
Utilizing quantitative real time PCR (qPCR) analysis, we
observed a significant up-regulation of OA gene expression
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in muscles of 6-week HRNF animals (p < 0.01) compared
to food restricted only control (FRC) rats (Fig. 1a). These
findings were confirmed using Western blot analysis,
which showed progressive increases in OA protein levels
with HRNF task performance compared to FRC rats
(Fig. 1b). The 65 kDa and 115 kDa molecular weight bands
of OA were increased (p < 0.01) while the 47 kDa band was
not increased with HRNF task performance (Fig. 1b-d). To
further examine the expression of OA in the muscle tissue
of our rat model, we performed immunohistochemistry
and subsequent quantification of OA in the flexor digi-
torum muscles of HRNF rats. OA immunostaining was
increased in 6-week HRNF muscles (p < 0.01) compared to
controls (Fig. 1e). OA was localized to the sarcolemma and
to macrophage-like cells located between individual muscle
fibers in 6-week HRNF muscles yet was absent in control
muscles (Fig. 1f and g).
MMP-1, -2, -3 and -13 are altered in flexor digitorum
muscles with HRNF task
Western blotting detection showed that MMP-1, -2
and -3 were significantly increased in 3- and 6-week
HRNF rat muscles compared to FRC rats (Figs. 2 and 3).
Specifically, the 54 kDa molecular weight band of MMP-1
(Fig. 2a and b) and the 66 kDa active form of MMP-2
(Fig. 2c and e) were increased in HRNF rat muscles (p <
Fig. 1 Osteoactivin (OA) expression increases in flexor digitorum muscles with high repetition negligible force (HRNF) task. a OA mRNA expression
levels (determined using quantitative PCR, qPCR) in muscles of food restricted control (FRC) rats and rats that had performed a HRNF food retrieval
task for 3 or 6 weeks. Values were normalized to GAPDH mRNA levels. b A representative Western blot of muscle homogenates probed with anti-OA.
Bands are at the expected molecular weights of OA in muscle (approximately 115, 65 and 47 kDa). β-actin was used as the loading control (at 42 kDa).
c, d Densitometric analysis of two OA bands (65 and 115 kDa) from three replicate Western blots normalized to β-actin levels. e Quantification of OA-
positive immunostaining as a percent of total tissue area. f, g Examples of OA immunostaining in longitudinal sections of FRC and HRNF rat muscles
showing OA in the myofiber sarcolemma (arrowheads) and macrophages (mac) only in HRNF muscles. Ct = connective tissue, M =muscle. *p< 0.05,
**p < 0.01, compared to FRC rats. Scale bars in F and G = 50 μm
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0.05 each), particularly by 6 weeks of task performance.
The 72 kDa latent form of MMP-2 did not change
significantly across groups (Fig. 2c and d). Expression
levels of the active forms of MMP-3 (45 kDa and
28 kDa) also increased significantly in 6-week HRNF
rats (p < 0.05 each) compared to 3-week HRNF and
FRC rat muscles (Fig. 3a, c and d). In contrast, the
latent form of MMP-3 (57–59 kDa) did not change
(Fig. 3a and c), and the level of active MMP-13
(48 kDa) decreased with HRNF task performance (p <
0.01) compared to controls (Fig. 3e and f ).
HSP72 increases in muscles and Co-localizes with OA in
sarcolemma of HRNF rats
ELISA analysis showed significant increased HSP72 pro-
tein in 6-week HRNF muscles (p < 0.05) compared to
controls (Fig. 4a). This result was supported by Western
blot analysis that confirmed the expression and increase
of the HSP72 protein in 6-wk HRNF rat muscles com-
pared to controls (Fig 4b). We also evaluated the expres-
sion of OA and HSP72 using immunohistochemical
methods. Little to no HSP72 or osteoactivin was ob-
served in FRC rat muscles (representative examples
Fig. 2 Matrix metalloproteinase (MMP)-1 and -2 protein levels increase in flexor digitorum muscles with high repetition negligible force (HRNF)
task. a Representative Western blot of muscle homogenates probed with anti-MMP-1. An immunoreactive band at the expected molecular weight
of 54 kDa was detected. β-actin was used as a loading control (42 kDa). b Densitometric analysis of the MMP-1 band from three replicate Western
blots were normalized to β-actin levels and documents significant increases relative to food restricted control (FRC) rats after 3 and 6 weeks of
the HRNF task and between 3 and 6 weeks of the task. c Representative Western blot of muscle homogenates probed with anti-MMP-2. Bands are
detected at the expected molecular weights for the latent (72 kDa) and active (66 kDa) forms. d, e Densitometric analyses of the MMP-2 protein bands
(72 and 66 kDa) from three replicate Western blots after normalization to β-actin levels show that only the active form is increased.
*p < 0.05, **p < 0.01, compared to FRC rats; ns = not significant
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shown in Fig. 4c and d). Double labeling immunohisto-
chemistry in 6-week flexor digitorum muscles demon-
strated increased expression of HSP72 (in red; Fig. 4e, g)
and OA (in green; Fig. 4f, g), with co-localization in the
sarcolemma surrounding the myofibers (Fig. 4g). Quan-
tification of HSP72 immunostaining confirmed its in-
creased immunoexpression in 6 week HRNF rat muscles
compared to controls (Fig. 4h). No DAPI labeled cell
bodies were visualized within the center of any of the
myofibers at this 6-week HRNF time point (data not
shown), indicating that the myofibers were not injured.
Osteoactivin and HSP72 increase in tendons with HRNF
task
Next, we examined the expression of OA and HSP72 in
flexor digitorum tendons. Western blot analysis showed
that only the 47 kDa form of OA was increased in
tendons of 6-week HRNF task performance (p < 0.01)
compared to FRC rats (Fig. 5a and b). Immunoexpres-
sion of OA and its quantification showed significantly
increased OA immunostaining in 6-week HRNF tendons
(p < 0.05) compared to control rat tendons (Fig. 5c-f ).
OA was localized to tenocytes within 6-week HRNF
tendons and to fibroblast- and macrophage-like cells
located within the surrounding connective tissue (epi-
tendon), but was absent in control tendons and epiten-
don (Fig. 5d-f ). Similarly, HSP72 immunostaining was
significantly increased in tenocytes located within 6-
week HRNF tendons compared to controls (Fig. 5g-i).
MMP-1 and -3 increase in tendons with HRNF task
Western blot analysis showed the level of MMP-1
(54 kDa) was increased in 6-week HRNF rat tendons
(p < 0.05), compared to 3-week HRNF and FRC rat
Fig. 3 Matrix metalloproteinase (MMP)-3 levels increase whereas MMP-13 decreases in flexor digitorum muscles with high repetition negligible
force (HRNF) task. a Representative Western blot of muscle homogenates probed with MMP-3. Bands are at the expected molecular weights of
latent and active forms of MMP-3 (approximately 57–59, 45, and 28 kDa). β-actin was used as a loading control. b-d Densitometric analysis of
latent (57–59 kDa) and active (45 and 28 kDa) bands of MMP-3 from three replicate Western blots were normalized to β-actin levels.
e A representative Western blot of muscle homogenates probed with MMP-13. Doublet bands observed at the expected molecular weight of active
MMP-13 (approximately 48 kDa) were analyzed, averaged and normalized to the loading control. f Densitometric analysis of active (48 kDa) form of
MMP-13 from three replicate Western blots after normalization to β-actin levels shows that it decreased significantly with the HRNF task. *p< 0.05,
**p < 0.01, compared to FRC rats; ns = not significant
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tendons (Fig. 6a and b). Note the variability of MMP-
1 in the 3-week HRNF tendons (Fig. 6a). This was a
consistent finding. We next found that the latent
(57–59 kDa) and active (45 kDa) forms of MMP-3
were increased significantly in 6-week HRNF rat ten-
dons (p < 0.05) compared to 3-week HRNF and FRC
rats (Fig. 6c-e). Variable expression of the latent
forms of MMP-3 was observed in FRC and 3-week
Fig. 4 Heat shock protein 72 (HSP72) increases in flexor digitorum muscles of high repetition negligible force (HRNF) rats and co-localizes with
osteoactivin (OA) in the sarcolemma. a ELISA of HSP72 protein levels in FRC and HRNF rat muscle lysates. Nanograms of protein were normalized
to μg of total protein. b Representative Western blots of muscle homogenates probed with anti-HSP72 were used to confirm that the molecular
weight of the HSP protein recognized by the antibody was the inducible form of HSP72. c Immunostained image of HSP72 (red) in muscle from
a food restricted control (FRC) rat (a proximal portion of the muscle was resected and cut transaxially and shown), showing that there was little
to no immunostaining. d Immunostained images of OA (green) in muscle from a FRC rat (a proximal portion of the muscle was resected and cut
transaxially and shown) showing little to no immunostaining. e-g Double-labeled immunostained images of HSP72 (red) and OA (green) were
merged in muscle images from an 8-week HRNF rat (a proximal portion of the muscle was cut transaxially and is shown). Arrows indicate HSP72
and OA co-localization in myofiber sarcolemma. The insets in e-g show enlarged regions of these images to illustrate co-localization of HSP72
and OA in myofiber sarcolemma. h Quantification of HSP72-positive immunostaining as a percent of total tissue area. *p < 0.05, compared to FRC
rats. Scale bars in C-G = 50 μm
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HRNF tendons, while the active form of MMP-3
(45 kDa) was consistently increased in the 6-week
HRNF tendons.
IL-1alpha and IL-1beta alter across time in muscles and
tendons with HRNF Task
Lastly, we also observed transient yet significant in-
creases of IL-1alpha in 3-week HRNF tendons (Fig. 7b)
and IL-1beta in 3-week HRNF muscles (Fig. 7c). We also
observed a very small but significant decrease in IL-
1alpha in 6-week HRNF muscles compared to controls
(Fig 7a). No increase was observed for IL-1beta in
tendons (Fig. 7d). TNF-alpha and IL-10 did not alter sig-
nificantly with task performance in either tissue com-
pared to controls (data not shown).
Discussion
For the first time to our knowledge, we show in a rat
model of limb overuse that expression of the growth
factor osteoactivin (OA) increases progressively in
forearm muscles and tendons with prolonged perform-
ance of an upper extremity high repetition negligible force
(HRNF) task for up to 6 weeks. Immunostaining also
showed localization of OA to myofiber sarcolemma,
Fig. 5 Flexor digitorum tendons show increased osteoactivin (OA) and heat shock protein 72 (HSP72) by six weeks of high repetition negligible
force (HRNF) task performance. a Representative Western blot of tendon homogenates probed with anti-OA. Band detected is the 47 kDa MW.
β-actin was used as a loading control (at 42 kDa). b Densitometric analysis of the 47 kDA OA band in tendon from three replicate Western blots
after normalization to β-actin levels. c-f Immunostaining and quantification of OA in food restricted control (FRC) and HRNF rat tendons
(T). A tendon region located proximal to the wrist and cryosectioned longitudinally, is shown. Arrows indicate representative OA-immunopositive cells,
many of which are tenocyte-like in appearance. Fibroblast-like cells were also observed in the epitendon (one indicated with an asterisk in panel E and
enlarged in the inset) as well as macrophage-like cells (arrow heads). g-i Immunostaining and quantification of HSP72 in FRC and HRNF rat tendons
(T). Arrows indicate representative HSP72-immunopositive cells that appear tenocyte-like. *p< 0.05, **p < 0.01, compared to FRC rats. Scale bars in
D-F,H = 50 μm; Scale bar in G = 100 μm. n.s. = not significant.
Frara et al. BMC Musculoskeletal Disorders  (2016) 17:34 Page 9 of 14
macrophage-like cells, fibroblast-like cells and tenocytes.
Levels of enzymatic proteins related to tissue turnover,
MMP-1, -2 and -3, also progressively increased, whereas
MMP-13 decreased, in forearm muscles with HRNF task
performance. MMP-1 and -3 levels also progressively in-
creased in forearm tendons. Levels of a known repair pro-
tein, HSP72, also increased only in 6-week HRNF muscles
and tendons compared to controls, and co-localized with
OA immunoexpression in the sarcolemma of 6-week
HRNF muscles.
We have previously shown modest muscle and tendon
injury, followed by a low-grade but transient inflamma-
tory response, with performance of this HRNF reaching
and food retrieval task [9, 35]. Since inflammation oc-
curring in injured tissues as a consequence of overuse is
thought to be related to repair processes [40], we
extended our past studies to examine repair and remod-
eling factors in this current study. Repair of musculo-
skeletal tissues may be driven by a number of anabolic
factors. We examined OA because it has been identified
Fig. 6 Matrix metalloproteinase (MMP)-1 and -3 protein levels increase in flexor digitorum tendons with high repetition negligible force (HRNF)
task. a Representative Western blot of tendon homogenates probed with anti-MMP-1. Bands are at the expected molecular weight of 54 kDa.
β-actin used as a loading control (at 42 kDa). b Densitometric analysis of three replicate Western blots shows the ratio of the MMP1 band after
normalization to β-actin levels. c A representative Western blot of muscle homogenates probed with MMP-3. Bands are at the expected molecular
weights of latent and active forms of MMP-3 (approximately 57–59 and 45). β-actin used as a loading control. d, e Densitometric analysis of latent
(57–59 kDa) and active (45 kDa) forms of MMP-3 from three replicate Western blots after normalization to β-actin levels. *p < 0.05, **p < 0.01,
compared to FRC and 3 week rats. n.s. = not significant.
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as an anabolic growth factor in long bones [41], and
found that it was increased in muscles and tendons of
HRNF rats, with the greatest increases in parallel with a
return of inflammatory cytokines to baseline levels. The
increase in OA was concomitant with increased MMP
and HSP72, proteins known to participate in repair and
remodeling processes, thus further supporting a role for
OA as an anabolic molecule. Several studies have shown
that OA regulates cell proliferation, adhesion, differenti-
ation and synthesis of extracellular matrix proteins in
various cell types under normal and repair/regeneration
conditions [16, 41–49]. In skeletal muscle, OA increases
after denervation or distraction injury [14–16, 50] and
has been shown to up-regulate MMP-3 and -9 expres-
sion in fibroblasts infiltrating denervated skeletal muscle
[16]. Extracellular fragments of OA produced by ectodo-
main shedding induce MMP-3 expression in myofibro-
blasts after unloading [14]. These latter responses serve
to enhance tissue turnover and repair.
Tissue injury is known to induce the expression of
matrix-related genes, including MMPs [51–54]. There-
fore, we examined their expression and observed that
performance of the HRNF task for 6 weeks increased
MMP expression and found that MMP-1 (collage-
nase), -2 (gelatinase) and -3 (stromelysin-1) were in-
creased in flexor digitorum muscles, while MMP-1
and -3 were increased in tendons. We have previously
shown that MMP-2 increases in serum, forearm mus-
cles and tendons of rats performing a high repetition
low force lever-pulling task for 18 weeks [55]. MMPs
are zinc-dependent proteases that regulate cell-matrix
composition, modulate ECM turnover, and are pro-
duced by fibroblasts, mesenchymal cells and macro-
phages [56–59]. The expression of most MMPs is low
in normal steady-state tissues and are induced only
when ECM remodeling is needed [60], such as for
musculoskeletal tissue adaptability to loading and
training [61–63]. Their expression is transcriptionally con-
trolled by growth factors, cell-cell and cell-matrix interac-
tions [64–66] and inflammatory cytokines [62, 63].
Examination of an experimental model of muscle regener-
ation [cardiotoxin (CTX) injection] shows a tightly regu-
lated time course of MMP activation and resolution of
tissue damage [52, 67, 68]. Also, generalized MMP inhib-
ition impairs muscle repair [69] further supporting their
requirement in resolution of muscle damage [70].
In tendons, MMPs are involved in collagen catabolism
and show increased activity with prolonged periods of
high or low mechanical loading or during periods of ten-
don repair [71–73]. Studies have shown increased
MMP-1 or MMP-2 with chronic loading of tendons [74]
in tendons with signs of overuse injury [75, 76] and in
flexor tendosynovial tissues collected from patients with
carpal tunnel syndrome [77]. In agreement with our
Fig. 7 ELISA of inflammatory cytokines in flexor digitorum muscles and tendons of reach limb. Data is shown for (a, b) interleukin (IL-1) alpha and
(c, d) IL-1beta in food restricted control (FRC) and 3- and 6-week HRNF rats. *p < 0.05, compared to FRC rats
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data, a synergistic effect of mechanical stretch and pres-
ence of inflammatory cytokines has been shown to in-
duce MMP-1 and -3 expression in tendon cells more
than stretch alone [78–80]. The increased MMPs with
HRNF task performance are likely responding to the
continued loading and transient increases of IL-1alpha
in tendons and IL-1beta in muscles and are contributing
to tissue remodeling for repair.
Since previous studies suggest that heat shock proteins
(HSPs) play a role in skeletal muscle repair after high-
force eccentric exercise and that elevated HSP70 and its
inducible form (HSP72) protects skeletal muscle against
further injury [28, 29], we examined its expression and
found that this stress-inducible protein was increased in
6-week HRNF muscles compared to controls. HSP72
plays a role in skeletal muscle remodeling and adapta-
tion processes in response to exercise and stress [81, 82].
Exercise training increases the expression of HSP72 a few
days after the onset of training [83–85] while prolonged
exercise training, using intermittent high-intensity tread-
mill running for 8 weeks, induces long-term enhancement
of HSP70 expression in skeletal muscle [86]. Interestingly,
Sjogaard et al. showed in human subjects that perform-
ance of repetitive tasks increased HSP72 in muscles while
prolonged exercise training decreased its basal levels [87],
suggestive of a clear difference between these two activ-
ities. Activation of HSP72 may play a dual role in inflam-
mation [88], inhibiting the release of inflammatory
cytokines including IL-1beta [89–93]. This interaction be-
tween HSP72 and inflammatory cytokines may explain
our findings of only low levels of IL-1alpha and beta by
6 weeks of task performance.
As mentioned above, since HSP72 stimulate anti-
inflammatory cytokines and inhibit the release of some
inflammatory cytokines, we next examined the muscles
and tendons for presence of inflammatory cytokines. We
observed that performance of a HRNF task for 3 weeks
induces significant increases in IL-1alpha in tendons and
IL-1beta in muscles, yet declines to baseline or even
below baseline levels by 6 weeks of task performance.
Since pro-inflammatory cytokine expression are induced
at early time points during tissue repair [94], we suggest
that the 3 week time point is the peak of inflammatory
phase in this high repetition negligible force reaching
and grasping model, and that the 6-week time point is
the beginning of the repair proliferative phase, with
HSP72 and OA mediating tissue repair and adaptation.
Conclusions
These findings suggest that performance of a high repe-
tition negligible force reaching and grasping induces an
inflammatory response at 3 weeks and then a repair re-
sponse at 6 weeks that might be mediated, at least in
part, by OA, MMPs and HSP72. Further research is
needed to determine the production of these proteins in
musculotendinous tissues undergoing higher levels of
persistent overloading and tissue injury, such as in ani-
mals and humans performing a high repetition high
force task for longer periods of time.
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